Alkermes announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place… read more.
A new online survey conducted by The Harris Poll on behalf of Alkermes, sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64… read more.
Alkermes announced the presentation of research related to Lybalvi (olanzapine and samidorphan) and Aristada (aripiprazole lauroxil), the company’s commercial products in psychiatry, and ALKS 2680, an investigational medicine… read more.
Alkermes announced that the FDA has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
